Literature DB >> 28436620

Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide.

Vimal K Udhayakumar1, Ans De Beuckelaer1, Joanne McCaffrey2, Cian M McCrudden2, Jonathan L Kirschman3, Daryll Vanover3, Lien Van Hoecke1,4, Kenny Roose1,4, Kim Deswarte5,6, Bruno G De Geest7, Stefan Lienenklaus8, Philip J Santangelo3, Johan Grooten1, Helen O McCarthy2, Stefaan De Koker1,4.   

Abstract

To date, the mRNA delivery field has been heavily dominated by lipid-based systems. Reports on the use of nonlipid carriers for mRNA delivery in contrast are rare in the context of mRNA vaccination. This paper describes the potential of a cell-penetrating peptide containing the amphipathic RALA motif to deliver antigen-encoding mRNA to the immune system. RALA condenses mRNA into nanocomplexes that display acidic pH-dependent membrane disruptive properties. RALA mRNA nanocomplexes enable mRNA escape from endosomes and thereby allow expression of mRNA inside the dendritic cell cytosol. Strikingly, RALA mRNA nanocomplexes containing pseudouridine and 5-methylcytidine modified mRNA elicit potent cytolytic T cell responses against the antigenic mRNA cargo and show superior efficacy in doing so when compared to RALA mRNA nanocomplexes containing unmodified mRNA. RALA's unique sequence and structural organization are vital to act as mRNA vaccine vehicle, as arginine-rich peptide variants that lack the RALA motif show reduced mRNA complexation, impaired cellular uptake and lose the ability to transfect dendritic cells in vitro and to evoke T cell immunity in vivo.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD8+ T cell responses; RALA mRNA nanocomplexes; cpp; endosomal escape; mRNA vaccines

Mesh:

Substances:

Year:  2017        PMID: 28436620     DOI: 10.1002/adhm.201601412

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  37 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

2.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

3.  Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery.

Authors:  Céline Lacroix; Almudena Humanes; Céline Coiffier; Didier Gigmes; Bernard Verrier; Thomas Trimaille
Journal:  Pharm Res       Date:  2020-01-08       Impact factor: 4.200

Review 4.  Nutrients Interaction with the Immune System.

Authors:  S Noor; S Piscopo; A Gasmi
Journal:  Arch Razi Inst       Date:  2021-12-30

Review 5.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

Review 6.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

Review 7.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

8.  mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.

Authors:  Yuhua Wang; Lu Zhang; Zhenghong Xu; Lei Miao; Leaf Huang
Journal:  Mol Ther       Date:  2017-11-21       Impact factor: 11.454

Review 9.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 10.  mRNA vaccines manufacturing: Challenges and bottlenecks.

Authors:  Sara Sousa Rosa; Duarte M F Prazeres; Ana M Azevedo; Marco P C Marques
Journal:  Vaccine       Date:  2021-03-24       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.